首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions
【24h】

Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions

机译:预甲状腺细胞移植中预翻封指数的影响:在索引基础决策之前关键在于中心特定的结果数据

获取原文
获取原文并翻译 | 示例
           

摘要

Outcome after allogeneic hematopoietic stem cell transplantation is influenced by patient comorbidity, disease type, and status before treatment. We performed a retrospective study involving 521 consecutive adult hematopoietic stem cell transplantation patients who underwent transplantation for hematological malignancy at our center from 2000 to 2012 to compare the predictive value of the hematopoietic cell transplantation specific comorbidity index (HCT-CI) and the disease risk index (DRI) for overall survival and transplantation related mortality. Patients in the highest HCT-CI risk group (HCT-CI score had a lower 5-year overall survival rate (50%) than the low-risk group (63%; P<.01). Subset analysis of donor origin showed greater 5-year overall survival in siblings than in matched unrelated donors, regardless of HCT-CI score (eg, 67% 5-year overall survival in siblings despite an HCT-CI score of >6 [n = 9]). Five-year overall survival in the highest DRI risk group was significantly poorer (44%) than in the low-risk group (63%; P<.01). Both indices failed to predict differences in transplantation-related mortality (HCT-CI, P=.54; DRI, P=.17). We conclude that HCT-CI and DRI were predictive of overall survival in our patient population. Even so, our data show that different patient groups may have different outcomes despite sharing the same index risk group and that indices should, therefore, be evaluated according to local data before clinical implementation at the single-center level. (C) 2017 American Society for Blood and Marrow Transplantation.
机译:同种异体造血干细胞移植后的结果受患者合并症,疾病类型和治疗前的地位影响。我们进行了回顾性研究,涉及521个连续成年造血干细胞移植患者,他们从2000〜2012年接受了我们中心移植的血液恶性恶性肿瘤,比较了造血细胞移植特异性合并症指数(HCT-CI)的预测值和疾病风险指数(DRI)整体存活和移植相关死亡率。最高HCT-CI风险组(HCT-CI评分的患者较低的5年总存活率(50%)比低风险组(63%; P <.01)。捐赠者来源的子集分析显示得更大兄弟姐妹的5年总体生存比匹配的无关捐助者,无论HCT-CI得分如何(例如,兄弟姐妹的67%的5年总生存率,尽管HCT-CI得分> 6 [n = 9])。五年最高DRI风险组的整体生存率显着较差(44%)而不是低风险组(63%; P <.01)。两种索引未能预测移植相关死亡率的差异(HCT-CI,P = .54; DRI,P = .17)。我们得出结论,HCT-CI和DRI在患者人口中预测了整体生存率。即使是,我们的数据表明,尽管共享了相同的指标风险组,但我们的数据可能有不同的结果。因此,该指数应该根据单中心级别的临床实施之前根据当地数据进行评估。(c)2017年美国血和MA Rrow移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号